Risk of anti-TNF therapy on pregnancy, breastfeeding, live vaccines and related information in patients with inflammatory bowel disease: Real-world data from a nationwide study.

Date publication

juillet 2024

Journal

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Bendaoud S, Nahon S, Beaugerie L, Gornet JM, Wils P, Amiot A, Peyrin-Biroulet L, Abitbol V, Hébuterne X, Altwegg R, Rosa I, Amil M, Heluwaert F, Plastaras L, Stefanescu C, Quentin V, Antoni M, Bideau K, Boualit M, Cuillerier E, Locher C, Skinazi F, Boureille A, Buisson A, Simon M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38981787

Résumé

Anti-TNF are usually maintained during pregnancy in patients with inflammatory bowel disease (IBD) but safety is still a concern for them.

Mots clés

Anti-TNF therapy, Breastfeeding, Inflammatory bowel disease, Live vaccines, Pregnancy

Référence

Dig Liver Dis. 2024 07 8;: